Tvardi Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Raymond James Financial

Raymond James Financial began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $62.00 price target on the stock. Raymond James Financial’s target price would indicate a potential upside of 137.46% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Oppenheimer began coverage on Tvardi Therapeutics in a research report on Wednesday, May 21st. They issued an “outperform” rating and a $65.00 price target for the company. Wall Street Zen upgraded Tvardi Therapeutics to a “hold” rating in a report on Saturday, May 24th. Piper Sandler began coverage on Tvardi Therapeutics in a research report on Thursday, June 12th. They set an “overweight” rating and a $78.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Tvardi Therapeutics in a report on Friday, July 11th. They set an “overweight” rating and a $52.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $64.25.

Tvardi Therapeutics Price Performance

Shares of NASDAQ:TVRD opened at $26.11 on Monday. Tvardi Therapeutics has a 52 week low of $8.13 and a 52 week high of $34.31.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.